Futura Medical has proprietary transdermal technology which can be incorporated into formulations of well characterised drugs to improve performance and extend their uses. Headline results from a clinical trial assessing its three pain portfolio products suggest that its anti-inflammatory drugs applied locally are ‘not inferior’ to formulations of the established gold standards. These should provide a value inflection point, with further potential uplift when management concludeslicensing deals with commercial partner(s).
